按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了桂林三金药业股份有限公司（以下简称桂林三金公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是桂林 三金公司董事会的责任。 二、注册会计师的责任 目 录 一、内部控制审计报告………………………………………………第 1—2 页 内部控制审计报告 天健审〔2025〕7907 号 桂林三金药业股份有限公司全体股东： 我们认为，桂林三金公司于 2024 年 12 月 31 日按照《企业内部控制基本规 第 1 页 共 2 页 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 天健会计师事务所（特殊普通合伙） 中国注册会计师： 方国华 中国·杭州 中国注册会计师： 王剑飞 二〇二五年四月二十四日 第 2 页 共 2 页 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表………………第 3 页 专项审计说明 天健审〔2025〕7906 号 桂林三金药业股份有限公司全体股东： 我们接受委托，审计了桂林三金药业股份有限公司（以下简称桂林三金公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的桂林三金公司管理层编制的 2024 年度《非经营性资金占用及其他关联资金 往来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供桂林三金公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为桂林三金公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解桂林三金公司 2024 年度非经营性资金占用及其他关联资金 往来情况，汇总表应当与已审的财务报表一并阅读。 二、管 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥466,571,831.61, a decrease of 3.32% compared to ¥482,586,774.29 in the same period last year[5] - Net profit attributable to shareholders increased by 4.80% to ¥104,816,228.19 from ¥100,017,772.21 year-on-year[5] - The basic earnings per share rose by 5.88% to ¥0.18, up from ¥0.17 in the same period last year[5] - Net profit for the current period is 104,816,228.19, compared to 100,017,772.21 in the previous period, indicating a growth of approximately 3%[21] - Other comprehensive income for the current period is 18,185,554.41, a significant improvement from -9,270,924.95 in the previous period[21] Cash Flow - The net cash flow from operating activities surged by 82.37% to ¥45,690,928.80, compared to ¥25,053,971.39 in the previous year[5] - Cash flow from operating activities decreased to 485,577,611.65 from 505,614,745.70, indicating a decline in cash generation from core operations[22] - Net cash flow from operating activities was $45,690,928.80, an increase from $25,053,971.39 in the previous period, indicating a positive trend in operational efficiency[23] - Net cash flow from financing activities was $65,947,402.45, a recovery from a negative cash flow of $101,543,337.74 in the previous period, showing improved financing conditions[24] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.37% to ¥4,332,605,500.47 from ¥4,232,210,339.05 at the end of the previous year[5] - Total liabilities decreased to 1,199,827,966.86 from 1,222,434,588.04, reflecting a reduction in financial obligations[20] - Non-current liabilities increased to 240,606,597.60 from 226,976,635.54, indicating potential long-term financing strategies[20] - The company’s non-current assets decreased to ¥1,467,746,473.09 from ¥1,667,628,567.53, a decline of about 12%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,526[12] - The largest shareholder, Guilin Sanjin Group, holds 62.07% of shares, totaling 364,679,300 shares[12] - The first phase of the employee stock ownership plan holds 5,147,976 shares, representing 0.88% of total shares[12] Investment Activities - The company reported a 200.82% increase in cash received from investment activities, totaling ¥295,500,000.00, due to the redemption of financial products[10] - Total cash inflow from investment activities reached $599,961,141.23, significantly higher than $274,739,448.15 in the prior period, reflecting strong investment recovery[23] - Cash received from investment recovery was $295,500,000.00, compared to $98,233,131.97 previously, highlighting effective asset management[23] - Cash outflow for investment activities totaled $110,510,744.49, down from $391,146,730.70, suggesting a reduction in capital expenditures[23] Operational Efficiency - The company experienced a 61.43% decrease in cash received from other operating activities, amounting to ¥42,326,408.23, mainly due to reduced cash repayments[9] - The company completed the election of new independent directors, effective from April 13, 2025[14] - Research and development expenses increased to 38,346,676.10 from 33,086,145.88, highlighting a focus on innovation and new product development[20] Equity - The company’s total equity attributable to shareholders increased by 4.09% to ¥3,132,777,533.61 from ¥3,009,775,751.01 at the end of the previous year[5] - The total equity attributable to shareholders increased to 3,132,777,533.61 from 3,009,775,751.01, reflecting a strengthening of the company's financial position[20]

Financial Performance - The company's operating revenue for 2024 was approximately ¥2.19 billion, representing a 1.03% increase compared to ¥2.17 billion in 2023[21]. - Net profit attributable to shareholders for 2024 reached approximately ¥521.53 million, a significant increase of 23.79% from ¥421.30 million in 2023[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥396.25 million, up by 3.64% from ¥382.33 million in 2023[21]. - The basic earnings per share for 2024 was ¥0.89, reflecting a 23.61% increase compared to ¥0.72 in 2023[21]. - The total assets of the company at the end of 2024 were approximately ¥4.23 billion, a 7.52% increase from ¥3.94 billion at the end of 2023[21]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥3.01 billion, which is a 6.84% increase from ¥2.82 billion at the end of 2023[21]. - The net cash flow from operating activities for 2024 was approximately ¥588.33 million, an increase of 7.12% from ¥549.25 million in 2023[21]. - The company's weighted average return on equity for 2024 was 17.62%, up from 14.68% in 2023, indicating improved profitability[21]. Market and Industry Insights - The pharmaceutical manufacturing industry in China achieved a total revenue of 25,298.5 billion CNY in 2024, remaining flat year-on-year, while total profit decreased by 1.1%[32]. - The retail pharmacy market is projected to grow by 3.7% in 2024, with online pharmacies leading this growth at 14.4%[33]. - The online pharmacy market sales reached 758 billion CNY in 2024, reflecting a significant shift in consumer purchasing behavior[33]. - The company ranks 29th in the "Top 100 Chinese Traditional Chinese Medicine Enterprises" and 44th in the "Top 50 Comprehensive Competitiveness of Traditional Chinese Medicine Industry" for 2024[35]. Product Development and Innovation - The company has 47 unique specialty products and 79 valid invention patents, including 1 US invention patent[40]. - The company aims to strengthen its leadership in the throat and urinary health sectors, while also expanding into cardiovascular, neurological, respiratory, and digestive health[39]. - The company is committed to a dual-wing development strategy focusing on traditional Chinese medicine and biopharmaceuticals[39]. - The company launched 17 research projects in 2024, including 6 formal pipeline projects and 5 new drug discovery projects[76]. - The company is advancing multiple R&D projects, including BC006, BC008, and BC007, targeting late-stage solid tumors with ongoing Phase I clinical trials[89]. Regulatory and Compliance - The company acknowledges potential risks including industry policy changes, product price declines, and intensified market competition, urging investors to remain cautious[5]. - The government has implemented multiple policies to support the development of innovative drugs, emphasizing the importance of price management and medical insurance[38]. - The National Medical Insurance Bureau is reforming payment methods to enhance the efficiency of medical insurance fund usage and improve patient experience[37]. Marketing and Sales Strategies - The company has established a comprehensive marketing system across the country, ensuring reliable drug quality and competitive advantages[39]. - The company plans to adopt new marketing models to enhance brand competitiveness and promote products at the terminal level[120]. - The establishment of a specialized sales department aims to enhance market penetration of key products in the medical field, driving new sales growth points[124]. Shareholder Engagement and Governance - The company has implemented a cash dividend policy, having executed two cash dividends during the reporting period, demonstrating a commitment to returning value to shareholders[143]. - The governance structure of the company has been continuously improved, adhering to relevant laws and regulations, ensuring compliance with the standards set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[143]. - The company has established a shareholder communication mechanism to ensure that all shareholders, especially minority shareholders, are informed and can participate in decision-making processes[143]. Risk Management - The company acknowledges the long and uncertain drug development cycle, which is influenced by various factors, including technology, approval processes, and market competition, leading to risks in innovation and new product development failures[134]. - To mitigate R&D risks, the company will strengthen its R&D team, enhance the innovation system, and improve the evaluation mechanism throughout the R&D process, focusing on the transformation of R&D results in the biopharmaceutical sector[134]. - The company faces risks from intensified market competition due to centralized procurement and dynamic adjustments in the medical insurance catalog[130]. Employee and Operational Insights - The total number of employees at the end of the reporting period is 2,567, with 1,808 in the parent company and 759 in major subsidiaries[177]. - The company has 637 production staff, 1,022 sales personnel, and 555 technical staff, indicating a diverse workforce[177]. - The average training hours per employee in 2024 is 31.63 hours, with a total of 60,445.37 training hours planned[179]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting a revenue growth of 20%[138]. - The company is focusing on market expansion in Southeast Asia, targeting a 10% market share by the end of 2024[138]. - The company plans to enhance its digital marketing strategy, aiming for a 25% increase in online sales[138].

证券代码：002275 证券简称：桂林三金 公告编号：2025-006 桂林三金药业股份有限公司 关于独立董事取得独立董事培训证明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称"公司"）分别于2025年3月26日召 开第八届董事会第十二次会议、2025年4月11日召开2025年第一次临时股东大会， 审议通过了《关于补选公司第八届董事会独立董事的议案》，选举胡余嘉先生为 公司第八届董事会独立董事，并选举其担任公司第八届董事会审计委员会委员， 任期自2025年4月13日起至第八届董事会届满之日止。 （www.cninfo.com.cn）披露的《桂林三金药业股份有限公司独立董事候选人关 于参加独立董事培训并取得独立董事资格证书的承诺书》。 近日，公司收到独立董事胡余嘉先生的通知，其已经按照相关规定参加了深 圳证券交易所举办的上市公司独立董事任前培训（线上），并取得由深圳证券交 易所创业企业培训中心颁发的《上市公司独立董事培训证明》。 特此公告。 桂林三金药业股份有限公司 董 事 会 2025 年 4 月 24 日 截至20 ...

证券代码：002275 证券简称：桂林三金 编号：2025-005 桂林三金药业股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1.本次股东大会未出现否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、 会议召开情况 1.召开时间： （1）现场会议召开时间：2025年4月11日15:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年4 月11日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票时间为2025年4月11日9:15-15:00 期间的任意时间。 2.现场会议召开地点：广西壮族自治区桂林市临桂区人民南路9号公司四楼 会议室 3.召开方式：现场投票与网络投票相结合的方式 4.召集人：公司董事会 5.主持人：董事长邹洵先生 6.公司已于2025年3月27日在《中国证券报》《证券时报》《证券日报》及 巨潮资讯网发布了《关于召开2025年第 ...

中国北京市建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于桂林三金药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致：桂林三金药业股份有限公司 受桂林三金药业股份有限公司（以下简称"公司"）聘请，北京市通商律师 事务所指派律师（以下简称"本所律师"）出席了公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》（以下 简称"《公司法》"）、《上市公司股东会规则》《深圳证券交易所上市公司股 东会网络投票实施细则》等法律、法规、规章、规范性文件及《桂林三金药业股 份有限公司章程》（以下简称"《公司章程》"）的规定，对公司本次股东 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1.桂林三金药业股份有限公司（以下简称"公司"）拟为全资孙公司白帆生物科技（上海）有限公司（以 下简称"白帆生物"）（资产负债率超过70%）申请增加的授信额度800万提供保证担保，该担保额度在 公司2024年度为孙公司提供担保额度预计内。本次担保发生后，公司对白帆生物剩余可用担保额度为 3,000万元； 2.截至本公告披露日，公司及控股子公司实际担保余额为26,615.10万元，占公司最近一期经审计净资产 的9.45%。其中对白帆生物的实际担保余额为16,860.00万元，占公司最近一期经审计净资产的5.99%。 公司及控股子公司、控股孙公司未对合并报表外单位提供担保，也无逾期债务对应的担保余额、涉及诉 讼的担保金额及因被判决败诉而应承担的担保金额。敬请投资者充分关注担保风险。 一、担保情况概述 （一）担保的审议情况 桂林三金药业股份有限公司（以下简称"公司"）于2024年4月24日召开第八届董事会第九次会议、于 2024年5月16日召开2023年度股 ...

证券代码：002275 证券简称：桂林三金 公告编号：2025-004 桂林三金药业股份有限公司 关于为孙公司申请增加授信额度提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.桂林三金药业股份有限公司（以下简称"公司"）拟为全资孙公司白帆生 物科技（上海）有限公司（以下简称"白帆生物"）（资产负债率超过70%）申 请增加的授信额度800万提供保证担保，该担保额度在公司2024年度为孙公司提 供担保额度预计内。本次担保发生后，公司对白帆生物剩余可用担保额度为3,000 万元； 2.截至本公告披露日，公司及控股子公司实际担保余额为26,615.10万元， 占公司最近一期经审计净资产的9.45%。其中对白帆生物的实际担保余额为 16,860.00万元，占公司最近一期经审计净资产的5.99%。公司及控股子公司、控 股孙公司未对合并报表外单位提供担保，也无逾期债务对应的担保余额、涉及诉 讼的担保金额及因被判决败诉而应承担的担保金额。敬请投资者充分关注担保风 险。 一、担保情况概述 （一）担保的审议情况 桂林三金药业股份有限公司（以下简称"公 ...

桂林三金: 关于召开2025年第一次临时股东大会的 通知 证券代码：002275 证券简称：桂林三金 公告编号：2025-003 桂林三金药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称"公司"）于2025年3月26日召开第 八届董事会第十二次会议并通过决议，决定于2025年4月11日（星期五）召开公 司2025年第一次临时股东大会，现将本次股东大会的有关事项公告如下： （3）公司聘请的律师； 一、召开会议的基本情况 通过了《关于提请召开2025年第一次临时股东大会的议案》。 圳证券交易所业务规则和公司章程等的规定。 现场会议的召开时间：2025年4月11日（星期五）下午15:30； 网络投票时间：2025年4月11日。其中：通过深圳证券交易所交易系统投票 的时间为2025年4月11日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证 券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票时间为2025年4 月11日9:15-15:00期间的任意时间。 公 ...